In December 2023, the U.S. Food and Drug Administration approved the first medicine built on CRISPR gene-editing technology. The decision did more than clear a single treatment. It established that a therapy which rewrites a patient’s DNA could move through the same regulatory pathway used for conventional drugs, and it signaled to investors, hospitals and...
